A detailed history of Winning Points Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Winning Points Advisors, LLC holds 12,481 shares of BMY stock, worth $565,014. This represents 0.95% of its overall portfolio holdings.

Number of Shares
12,481
Previous 12,396 0.69%
Holding current value
$565,014
Previous $892,000 3.03%
% of portfolio
0.95%
Previous 1.14%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 21, 2023

BUY
$65.71 - $74.53 $5,585 - $6,335
85 Added 0.69%
12,481 $865,000
Q4 2022

Feb 10, 2023

SELL
$68.48 - $81.09 $7,875 - $9,325
-115 Reduced 0.92%
12,396 $892,000
Q3 2022

Oct 07, 2022

BUY
$0.13 - $76.84 $13 - $7,684
100 Added 0.81%
12,511 $902,000
Q1 2022

Apr 27, 2022

SELL
$61.48 - $73.72 $15,677 - $18,798
-255 Reduced 2.01%
12,411 $906,000
Q4 2021

Feb 16, 2022

BUY
$53.63 - $62.52 $13,675 - $15,942
255 Added 2.05%
12,666 $574,000
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $6,191 - $6,742
-100 Reduced 0.8%
12,411 $829,000
Q1 2021

May 13, 2021

BUY
$59.34 - $66.74 $2,670 - $3,003
45 Added 0.36%
12,511 $790,000
Q4 2020

Feb 01, 2021

SELL
$57.74 - $65.43 $5,774 - $6,543
-100 Reduced 0.8%
12,466 $773,000
Q4 2019

Feb 03, 2020

BUY
$49.21 - $64.19 $9,842 - $12,838
200 Added 1.62%
12,566 $807,000
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $12,831 - $15,213
-300 Reduced 2.37%
12,366 $621,000
Q4 2018

Nov 12, 2019

SELL
$48.76 - $63.23 $3,218 - $4,173
-66 Reduced 0.52%
12,666 $664,000
Q3 2017

Nov 12, 2019

SELL
$55.23 - $63.74 $7,732 - $8,923
-140 Reduced 1.09%
12,732 $812,000
Q2 2017

Nov 08, 2019

BUY
N/A
128 Added 1.0%
12,872 $724,000
Q4 2016

Nov 07, 2019

BUY
N/A
12,744
12,744 $745,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $96.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Winning Points Advisors, LLC Portfolio

Follow Winning Points Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winning Points Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Winning Points Advisors, LLC with notifications on news.